GHK-Cu peptide: research-only guide for UAE laboratories

What is GHK-Cu peptide?

GHK-Cu peptide is glycyl-L-histidyl-L-lysine copper(II) complex, a naturally occurring copper tripeptide found in human plasma that researchers study for its effects on gene expression, extracellular matrix remodelling, and tissue repair. This guide is written for UAE-based researchers and buyers comparing research-grade material. It covers mechanism of action, gene-expression data, skin/hair/wound models, handling and storage, regulatory status, and sourcing via Remy Research.

All discussion here refers to in-vitro cell-culture experiments, animal studies, and small cosmetic human trials. No dosing instructions, no human-use guidance, and no therapeutic promises are included. GHK-Cu is a research tool, not an approved drug.

GHK-Cu is a small copper-binding molecule first isolated from human plasma by Loren Pickart in 1973 as a factor that caused aged liver tissue to synthesise proteins characteristic of younger tissue (Pickart & Thaler, 1973). It has since become one of the most studied copper peptides in regeneration and skin aging research.

Typical research formats include lyophilised vials and pre-diluted aqueous pens. Both are supplied under research-use-only labelling to a ≥99% HPLC line standard.

From this article, you will gain:

• A clear understanding of what GHK-Cu is, what it stands for, and why it appears blue
• A summary of molecular mechanisms, gene regulation data, and collagen production pathways
• An overview of preclinical evidence across skin, hair, and wound healing models
• Practical guidance on storage, handling, and cold-chain logistics for UAE labs
• Current FDA regulatory status and how to source GHK-Cu through Remy Research

What does GHK-Cu stand for, and why is it important in research?

GHK-Cu stands for glycyl-L-histidyl-L-lysine copper(II) complex. This small copper peptide attracts significant research interest because it appears to function as a potent modulator of tissue repair, skin regeneration, inflammation, and gene expression across hundreds of human genes.

The peptide structure

The peptide component consists of three amino acids: glycine (Gly), histidine (His), and lysine (Lys). Together they form a high-affinity chelator for Cu²⁺ ions. In its physiological state, GHK binds copper(II) tightly, forming the copper complex known as GHK-Cu. The metal-free form, simply called GHK, is sometimes used in gene-expression experiments where researchers assume physiological copper availability in the culture environment (Pickart et al., 2015, BioMed Research International).

Age-related decline

GHK-Cu levels decline significantly as people age, impacting skin repair and regeneration capacity. Circulating GHK-Cu concentration in human plasma measures approximately 200 ng/mL in healthy individuals around age 20 and drops to roughly 80 ng/mL by age 60 (Pickart et al., 2015). This age-related decline is one reason why the compound interests researchers studying skin aging, slower healing, and anti aging pathways.

Relevance for UAE labs

For UAE laboratories, GHK-Cu is attractive because it is a small, chemically well-characterised molecule with published gene datasets and many reproducible in-vitro assays. Its consistent behaviour across experiments, combined with traceable certificates of analysis, HPLC purity data, and mass spectral identity confirmation, supports reproducible research. Labs can use it to study collagen synthesis, elastin production, glycosaminoglycan synthesis, and antioxidant mechanisms with high confidence in reagent quality.

The distinction between "GHK-Cu" and "GHK" matters for experimental design. When researchers refer to GHK copper, they mean the copper-complexed form. When they use "GHK" alone, the peptide may be studied without added metal, though downstream biology frequently depends on copper availability in the system.

Why is GHK-Cu blue, and what does the colour indicate?

GHK-Cu appears blue because Cu²⁺ coordinated with peptide ligands-specifically histidine nitrogen, amide nitrogen, and backbone oxygen donors-absorbs light in the red and orange region of the visible spectrum. The resulting blue to blue-violet colour is characteristic of copper(II) complexes with square-planar or distorted octahedral geometries. However, colour alone is not a purity test; it simply indicates that copper is present and complexed with the peptide.

What to expect visually

Lyophilised GHK-Cu powder can range from pale blue to blue-green depending on residual water content, hydration state, and excipients. When reconstituted, solutions should appear clear with a blue tinge. Cloudiness, brown discolouration, or visible precipitates suggest oxidation, free-copper species, or degradation and warrant investigation before use.

Non-copper GHK peptide (the tripeptide without metal) is typically off-white or slightly yellowish. Blue coloration develops only after copper is added and chelation occurs. Absence of blue in a supposedly copper-complexed sample may indicate incomplete complex formation or degradation.

Analytical verification matters more than colour

Within a research-only framing, labs should never rely on visual inspection to confirm identity or concentration. Instead, each batch should be accompanied by a certificate of analysis documenting HPLC purity (≥99% for research-grade material), mass spectrometry confirming the molecular ion and isotope pattern, and, where available, UV-Vis spectroscopy showing the visible-range absorption band of the Cu²⁺ complex. GHK-Cu purity verification requires third-party certificates of analysis, and GHK-Cu products should disclose concentration and batch numbers to ensure experimental reproducibility.

How does GHK-Cu peptide work at the molecular and cellular level?

GHK-Cu functions as a copper transport complex and broad gene-expression modulator, influencing extracellular matrix remodelling, inflammation, and antioxidant stress-response pathways in cell and animal models (Pickart et al., 2015, BioMed Research International; Pickart et al., 2018, Int. J. Mol. Sci.). Most mechanistic data come from in-vitro cell culture and animal studies; there are no confirmed systemic effects from large, controlled human trials.

GHK-Cu as a copper transport and signalling complex

GHK binds copper, acting as a cofactor for enzymes such as lysyl oxidase (critical for collagen cross-linking) and superoxide dismutase (a key antioxidant enzyme). Unlike free copper ions, which can be pro-oxidant and catalyse reactive oxygen species formation, the GHK-Cu compound buffers and localises copper delivery to cells under controlled conditions.

GHK is released from larger extracellular matrix proteins during injury or proteolysis-for example, from type I collagen chains and SPARC (secreted protein acidic and rich in cysteine). Its appearance in wound fluid suggests a role in injury-response signalling. GHK-Cu enhances fibroblast activity, promoting skin repair, and has been studied in keratinocytes, endothelial cells, and dermal fibroblasts, where observed effects include cell proliferation, migration, and modulation of matrix metalloproteinases and their inhibitors such as TIMP-1 and TIMP-2.

Gene-expression effects and pathway modulation

In a landmark 2018 analysis, Pickart and Margolina reported that GHK altered expression of about 31.2% of human genes by 50% or more in a global microarray dataset. Of the genes involved, approximately 59% were upregulated and 41% were downregulated (Pickart et al., 2018, Int. J. Mol. Sci., PMC6073405). GHK-Cu increases gene expression in 59% of human genes affected in this dataset.

Affected gene categories include:

• Extracellular matrix and skin remodeling: collagens, proteoglycans, integrins
• TGF-β signalling: growth-factor pathways central to tissue repair
• Antioxidant enzymes: superoxide dismutase, catalase
• DNA repair genes: relevant to UV-damage protection models
• Inflammatory mediators: NF-κB regulators, cytokine modulators
• Cancer-related genes: metastasis suppressors and tumour-suppressor pathways (in vitro only)

These are in-vitro gene-expression shifts measured in microarray experiments. They do not constitute direct proof of clinical benefits or risks in humans. Studies that used GHK without explicit copper addition often assumed physiological copper availability; effects may vary depending on copper load in the experimental system.

Collagen, matrix remodelling, and antioxidant activity

In fibroblast and keratinocyte studies, GHK-Cu stimulates collagen production and elastin production while promoting glycosaminoglycan synthesis (including dermatan sulfate and chondroitin sulfate). GHK-Cu modulates matrix metalloproteinases, regulating protein breakdown in the ECM-specifically reducing certain MMP expression while increasing tissue inhibitors of metalloproteinases.

GHK-Cu stimulates collagen and elastin synthesis in skin models and improves wound healing in animal studies. In rodent full-thickness skin wound models, GHK-Cu treatment accelerated wound contraction, improved granulation tissue formation, and enhanced angiogenesis. GHK-Cu enhances blood vessel growth during tissue repair, supporting oxygen and nutrient delivery to healing tissue. GHK-Cu reduces inflammation and oxidative stress in wounds through multiple anti oxidant actions: boosting SOD and catalase expression in wound tissue, binding reactive lipid peroxidation products such as 4-HNE and acrolein, and inhibiting iron release from ferritin.

GHK-Cu has anti-inflammatory and antioxidant properties that protect the skin in these preclinical systems. These molecular effects underlie the broad interest in GHK-Cu across skin, hair, and tissue regeneration research models.

What does research say about GHK-Cu and skin, hair, and wound repair?

Small cosmetic trials, in-vitro studies, and animal studies suggest that GHK-Cu has pro-repair and pro-regenerative activity across skin, hair, and wound models. However, the data are limited in sample size, duration, and endpoint reliability-they do not rise to drug-level evidence. Results apply to specific formulations and experimental conditions, not automatically to any product.

Skin aging and cosmetic models

In the Abdulghani 1998 pilot study, 20 healthy volunteers applied creams to thigh skin for one month (10 per pair of creams). Procollagen synthesis increased in 7 of 10 (70%) using the copper peptide (GHK-Cu cream) on histological examination, compared with 5 of 10 (50%) using vitamin C cream and 4 of 10 (40%) using retinoic acid (Abdulghani et al., 1998, Disease Management and Clinical Outcomes). This was a small cosmetic trial with cosmetic endpoints, not a therapeutic study.

Other small human cosmetic studies have reported changes in skin density, skin firmness, elasticity, wrinkle volume, and mottled pigmentation with topical GHK-Cu formulations applied over 12 weeks (71 and 67 women in two facial studies reviewed by Pickart 2015). GHK-Cu improves skin firmness and elasticity significantly in these limited cosmetic models, and those studies ran for 12 weeks. In one cosmetic-endpoint study, GHK-Cu reduced wrinkle volume by 55.8% and wrinkle depth by 32.8% compared with a control serum (Pickart 2018).

In vitro, keratinocytes and fibroblasts treated with GHK or GHK-Cu showed increased expression of DNA repair genes and reduced markers of oxidative damage upon UV exposure. These findings are exploratory-they support skin regeneration hypotheses but are not therapeutic trials.

Hair follicle and scalp research

Evidence for GHK-Cu and hair comes primarily from animal models and small cosmetic scalp studies showing changes in follicle size, higher ratios of anagen (growth phase) to telogen (resting phase) follicles, and increased hair density over several months. GHK-Cu can increase hair growth and thickness in models using viable follicles. GHK-Cu stimulates miniaturized yet viable hair follicles in these models. Proposed mechanisms include improved microcirculation, anti-inflammatory effects in scalp tissue, and growth-factor modulation around follicles.

Robust long-term controlled trials remain limited. Remy Research hosts a dedicated hair-loss comparison article covering AHK-Cu, GHK-Cu, and PTD-DBM for researchers interested in deeper follicle-specific data.

Wound healing and organ-injury models

Classic rodent wound studies show that GHK-Cu accelerated wound contraction, increased collagen deposition, and stimulated angiogenesis compared with controls. GHK-Cu stimulates wound healing through various mechanisms, including cytokine modulation, MMP regulation, and antioxidant defence enhancement. In diabetic or ischaemic wound models, GHK-Cu influenced inflammatory cytokine profiles and improved antioxidant markers in wound tissue.

Beyond skin, GHK-Cu has shown effects in non-skin tissues in animal or ex-vivo systems. In lung models, GHK reactivated COPD fibroblasts and restored ECM gene expression. Liver, bone, and stomach lining models also showed improvements in gene expression or histological repair after GHK treatment (Pickart et al., 2018). These preclinical results generate hypotheses rather than confirming safety or efficacy across the entire body in humans.

How is GHK-Cu used in topical vs laboratory vial formats?

Consumer cosmetic serums and creams containing copper peptides differ fundamentally from research-grade lyophilised or aqueous GHK-Cu supplied for in-vitro work. Remy Research sells research chemicals only and does not formulate finished skincare for end users.

Topical copper peptide serums and cosmetic formulations

Cosmetic products typically list "Copper Tripeptide-1" (INCI name) in creams, serums, or masks designed for topical use. These formulations focus on barrier-compatible pH and penetration enhancement. GHK-Cu is found in topical serums, creams, and scalp tonics across the cosmetics industry. Small cosmetic trials on face, neck, and eye areas have used endpoints such as wrinkle scores, skin quality metrics, elasticity measurements, and photodamage scales to evaluate these products.

GHK-Cu is usually avoided in conjunction with strong acids or vitamin C to prevent instability of the copper complex. Researchers interested in formulation science, layering with other actives, or comparing GHK-Cu vs copper peptide serum products can find a dedicated explainer on the Remy Research site.

Lyophilised vials and aqueous research pens

Lyophilised GHK-Cu in sealed vials is the standard format for in-vitro experimentation. Research-grade GHK-Cu must meet strict manufacturing standards, and each batch should be accompanied by a certificate of analysis documenting ≥99% HPLC purity and mass spectral identity. GHK-Cu purity can vary significantly between suppliers, making traceable COA documentation essential for reproducible data.

Pre-diluted aqueous pens offer a convenience format for labs requiring ready-to-use solutions at known concentrations, avoiding reconstitution steps. Remy Research offers both formats under research-use-only labelling:

• GHK-Cu 50 mg lyophilised vial
• Genovare GHK-Cu 100 mg aqueous pen
• Genovare GHK-Cu 500 mg aqueous pen

No reconstitution volumes, dosing, or administration guidance is provided. The focus is traceability, COA, and batch consistency.

How does GHK-Cu compare to AHK-Cu, BPC-157, and the GLOW blend?

GHK-Cu, AHK-Cu, BPC-157, and multi-peptide blends are structurally different research tools aimed at distinct biological questions. Copper peptides like GHK-Cu are popular in biochemical research for their regenerative properties in skin and wound models, whereas BPC-157 targets gastrointestinal and musculoskeletal tissue in animal studies. This comparison focuses on mechanism and evidence type, not on which peptide is "better."

Comparison table: GHK-Cu vs AHK-Cu vs BPC-157 vs GLOW blend

The following table summarises key differences for researchers selecting peptides based on target tissue and experimental model.

Researchers should choose based on target tissue, cell type, and available model systems rather than marketing claims. For those exploring multi-peptide synergy hypotheses, the GLOW blend explainer provides additional context on the rationale behind combining these other peptides.

How should lyophilised GHK-Cu be stored and handled in the lab?

Lyophilised GHK-Cu should be stored dry at controlled cold temperatures and protected from light and moisture. Specific conditions are defined on each product's certificate of analysis. These are general stability considerations; researchers must follow their own institution's standard operating procedures.

Stability considerations for GHK-Cu

Peptides are sensitive to heat, moisture, and repeated freeze-thaw cycles. Copper complexes may also be light-sensitive, and the GHK-Cu compound is no exception. Best practices include:

• Storing sealed vials with desiccant in a refrigerator (2–8 °C) or freezer (−20 °C) as specified by the supplier
• Minimising exposure to room temperature during handling
• Using aliquots to reduce degradation from repeated freeze-thaw cycles
• Maintaining documentation of lot numbers and expiry dates for full traceability

Once in aqueous solution, shelf life is shorter and depends on solvent composition, pH, and microbial controls. Reconstituted or pre-diluted formats should be used promptly or stored according to the product-specific stability data provided on the COA.

Cold-chain logistics and UAE delivery by Remy Research

Remy Research offers same-day delivery within Dubai on orders placed before 4 PM and next-day delivery across the rest of the UAE on orders placed before 12 PM, using cold-chain or insulated packaging depending on the product format.

On arrival, storage responsibility transfers to the receiving lab. Vials and pens should be moved immediately to appropriate refrigerators or freezers. For labs managing multiple peptide inventories, the peptide interactions and mixing guide provides additional handling context.

Is GHK-Cu FDA approved or regulated as a drug?

GHK-Cu is not an FDA-approved drug. No FDA-approved GHK-Cu drug product is currently available. Injectable GHK-Cu was previously on the FDA's Category 2 list and, as of 22 April 2026, sits on the "nominated but withdrawn" list for injectable routes. GHK-Cu for non-injectable routes is listed in 503A Category 1 (FDA list of May 14, 2026), meaning it is under evaluation but not approved. The FDA plans to consult its Pharmacy Compounding Advisory Committee (PCAC) on GHK-Cu before the end of February 2027.

Copper peptides are widely used as cosmetic ingredients (listed as "Copper Tripeptide-1") where they are regulated as cosmetics, not drugs, provided no therapeutic claims are made. FDA approval as a drug has not been granted for any GHK-Cu formulation.

GHK-Cu is not approved for self-injection or any other human use. Research-grade GHK-Cu sold by Remy Research is labelled "for research use only" and is not intended for human use or veterinary administration. For more detail on the broader FDA peptide reclassification landscape in 2026, Remy Research maintains a dedicated regulatory explainer.

How can UAE laboratories buy GHK-Cu peptide from Remy Research?

Remy Research supplies GHK-Cu to labs and professional researchers in the UAE under research-use-only terms. Clinical or compounding use is outside its scope; for research reagent needs, Remy Research supplies material with published analytical documentation.

To order, researchers can browse GHK-Cu products on the Remy Research website, add them to the cart and check out. Key differentiators include a ≥99% HPLC line standard, a published METS Lab batch report for the 50 mg vial (CU50V-001, 99.87% HPLC), transparent sourcing, and local stock enabling rapid UAE delivery.

The GHK-Cu Dubai skin research guide collects the skin-study data and the primary references behind them. Remy Research does not provide medical, dosing, or cosmetic-use advice. Products are research reagents, not consumer health products.

Key facts about GHK-Cu peptide (quick reference)

• Full name: glycyl-L-histidyl-L-lysine copper(II) complex (GHK-Cu)
• Chemical formula: C₁₄H₂₃CuN₆O₄⁺ (copper-complexed form, PubChem CID 71587328)
• Molecular weight: 402.92 g/mol (PubChem)
• Charge state: Cu²⁺ coordinated by peptide nitrogens (histidine imidazole, amide backbone) and oxygen donors
• Discovery: first isolated from human plasma by Loren Pickart in 1973 as an age-related regenerative factor
• Biological occurrence: present in human plasma, saliva, and urine; GHK-Cu levels decline significantly as people age (approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60)
• Gene modulation: GHK altered expression of about 31.2% of human genes by ≥50% in one microarray dataset (Pickart et al., 2018); approximately 59% upregulated, 41% downregulated
• Primary research domains: skin aging, collagen production, wound healing, hair growth, antioxidant and anti-inflammatory pathways, COPD and organ-injury models, and cancer-related gene expression in vitro
• Research purity standard: ≥99% HPLC, with identity confirmed by mass spectrometry

Conclusion and next steps for GHK-Cu peptide research

GHK-Cu is a well-characterised copper peptide with broad gene-level effects and promising preclinical data across skin aging, wound healing, hair biology, and inflammation models. Copper peptides like GHK-Cu continue to generate significant research interest, yet the compound lacks drug approval and the translation gap between animal data and confirmed human therapeutic outcomes remains substantial.

Suggested next steps for researchers:

1. Review primary literature on gene-expression datasets and wound models, starting with the Pickart 2015 and 2018 reviews cited below
2. Design in-vitro assays aligned with documented pathways-collagen production, antioxidant enzymes, MMP modulation-using validated cell lines and controls
3. Consult internal ethics and regulatory teams before initiating any new study involving animal or human tissue
4. Explore Remy Research's GHK-Cu product library and related peptides, including healing and recovery peptides, for combination study design

For research use only. Not for human or veterinary use.